Recently, the early work of cancer researcher William Coley of the ages, Coley noted that some patients have recovered from cancer after surgery and their condition is relieved or even cured.

Coley developed treatment based on killing bacteria, but failed to win the trust of other colleagues who questioned the effectiveness and safety of Coley's designed treatments. Although the starting point is to increase the potential anti-cancer benefits of the immune response, other researchers have also repeated Coley's method in the past few decades, but the results are mixed.

But now, the results released by scientists show that: Injecting bacteria can eradicate tumor tissue. The study was published in the journal Science Translational Medicine.

The advantage of using Clostridium novemaria is that it only "vigors" in an oxygen-deprived environment, such as those inside tumor tissues. Traditional therapy cannot play a role in the lack of necessary blood and oxygen inside the tumor tissue. However, hypoxia-tolerant microorganisms can "mount" infection and induce a strong immune response.

In their study, the researchers introduced a number of innovations: They removed the toxin gene from Clostridium novemaria and produced a safer C. novyi-NT. They decided to inject bacterial spores directly into the tumor instead of relying on the intravenous route.

The ability of lysed tumor cells of Clostridium species to grow in an oxygen deficient environment is significant. We show that attenuated Clostridium novedrasus (C. Novy NT) induces precise, tumor-local responses after intratumoral injection in rat orthotopic glioma models.

The study found that the intratumoral injection of C. Novi NT spores was well tolerated. In the spontaneous solid tumors of companion dog bearings, the most common toxicities were expected to be associated with bacterial infection.

It is well known that experimental models are often unreliable in predicting the response of patients to human cancers. Therefore, the use of naturally occurring tumors in dogs was investigated. The researchers directly injected C. noyvi-NT spores into the tumor sites of 16 dogs. Among them, six dogs had an anti-tumor response 21 days after the first treatment. Three of the six showed that the tumor was completely eliminated, and the length of the longest tumor of the other three dogs was at least reduced by 30%. The side effects most dogs experience are: typical bacterial infections such as fever, tumor abscess and inflammation.

Based on these encouraging results, the researchers injected C. novyi-NT spores intratumorally to treat human patients with advanced leiomyosarcoma and found that they could reduce bone and bone around the tumor.

Currently, researchers are testing the safety and effectiveness of this new method. Although these results are preliminary, researchers believe that C. novyi-NT may become a new weapon for immunotherapy cancer